Furthermore, the combined treatment of Abx and CEND-1 (or iRGD) peptide, a cyclic peptide that targets alpha V-integrin and neurophilin-1 and improves internalization of co-administered drugs into tumor cells, demonstrated an increased activity and acceptable safety profile in a clinical trial 47. The gene discussed is ITGAV; the disease is neoplasm.